Wonderlab Bio
Boston-based regenerative medicine company that has built the world’s largest fully characterized, HLA-matched allogeneic iPSC cell bank. Its platform is designed to enable off-the-shelf cell therapies without routine immunosuppressive drugs.
INDUSTRY
Regenerative Medicine, Cell & Gene Therapy
SECTOR
Biotech / Regenerative Medicine / Cell Therapy
FOCUS
Off-the-Shelf Cell Therapy, iPSC Platform, Drug Discovery Tools
TECHNOLOGY
HLA-Matched Allogeneic iPSC Cell Bank
STAGE OF INVESTMENT
Series A
HEADQUARTERS
Boston, MA
WEBSITE
The real opportunity is the infrastructure WonderLab has built. One proprietary cell bank can support research tools today and multiple therapeutic programs tomorrow, creating several paths to value from the same underlying platform.
Chris Yoo, PhD
Fund Manager
What they do.
WonderLab Bio has built a fully characterized, HLA-matched allogeneic iPSC cell bank designed to support off-the-shelf regenerative medicine. By matching donor immune profiles across broad patient populations, its platform is designed to enable standardized cell therapies while reducing the need for patient-specific manufacturing and routine immunosuppression.
Why we invested.
We look for platforms with defensible infrastructure that can create value across more than one market. WonderLab stood out because its proprietary iPSC bank supports a commercial research-tools business today while also providing the foundation for a growing therapeutic pipeline. That gives the company multiple opportunities to create value from the same core platform rather than relying on a single product or indication.
Leadership
Robin Smith
Founder & CEO
